
Sava’s $36 million round brings a commercial partner to a difficult hardware journey
Evaluate each development milestone on its own evidence; a financing round is not approval to market a medical device.
YOUR DAILY PERSPECTIVE
Saturday, October 10, 2026

Evaluate each development milestone on its own evidence; a financing round is not approval to market a medical device.

A research-tool business needs repeatable measurements and usable workflows alongside technical novelty.

Separate investor conviction from product acceptance criteria, especially when the architecture is unfamiliar.

The authority granted to an evaluation harness deserves the same scrutiny as the model being evaluated.

Separate the hosted-service exit from the runtime decision, and test stateful behaviour before moving production.

Judge telemetry improvements by whether they preserve diagnostic value, not just by how much data disappears.

A repeatable test still needs a correct expectation. Evaluate what the suite catches, not only how quickly it runs.

Separate a software-identified opportunity from a verified, recoverable saving.

Expansion becomes durable when replenishment and cash conversion improve alongside sales.

Treat marketplace access as a sales channel, and verify the purchasing terms before committing delivery capacity.